Menu
Back to Journals » Journal of Multidisciplinary Healthcare » Volume 16
Potential Effects of Traditional Chinese Medicine on COVID-19 and Cardiac Injury: Mechanisms and Clinical Evidence
Received 2 June 2023
Accepted for publication 30 August 2023
Published 22 September 2023 Volume 2023:16 Pages 2863—2872
DOI https://doi.org/10.2147/JMDH.S424078
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Leilei Fan,1 Xue Ding2
1Department of Cardiovascular, Yellow River Central Hospital, Zhengzhou, 450004, People’s Republic of China; 2Department of Medical, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, People’s Republic of China
Correspondence: Xue Ding, Department of Medical, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, People’s Republic of China, Email [email protected]
Abstract: Coronavirus disease 2019 is a “Public Health Emergency of International Concern” from 30 January 2020 to 5 May 2023. While battling Coronavirus disease 2019, the Chinese government has actively promoted the collaborative treatment model of Western medicine and traditional Chinese medicine, and clinical and scientific research has applied appropriate and rigorous methodology. Severe acute respiratory syndrome coronavirus 2 infection may damage the cardiovascular system via an unclarified pathogenic mechanism. The National Health Commission of China recommends ‘three formulas and three medicines’ for the treatment of coronavirus disease 2019, which have been shown to be most effective in the treatments. Data from randomized controlled trials of ‘three formulas and three medicines’ suggested that the traditional Chinese medicine is safe and can alleviate the symptoms of cardiac injury. Therefore, we further evaluate the benefits and safety of traditional Chinese medicine treatment for Coronavirus disease 2019 patients with cardiac injury across the care continuum.
Keywords: traditional Chinese medicine, coronavirus disease 2019, cardiac injury
Introduction
Coronavirus disease 2019 (COVID-19) is a “Public Health Emergency of International Concern” from 30 January 2020 to 5 May 2023.1 According to the current data, 20–36% of patients with COVID-19 develop acute myocardial injury and have a higher mortality rate than those without cardiac injury, associated with the degree of elevation of the serum cardiac troponin (cTn) concentration.2–4 Although the morbidity of cardiovascular disease (CVD) has decreased in recent years, it remains a major healthcare challenge, especially for the elderly.5 Patients with COVID-19 and type 1 myocardial infarction have more symptoms and higher cardiogenic shock and mortality compared with the pre-COVID-19 population.6 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes overproduction of inflammatory cytokines, leading to systemic inflammation and multi-organ dysfunction syndrome that severely affect the cardiovascular system. Furthermore, in patients with heart failure (HF), monocytes produce more tumor necrosis factor (TNF)-α and less interleukin (IL)-10 than healthy subjects.7 A higher incidence of HF has been observed in patients hospitalized with COVID-19 and in intensive care units (ICU).8,9
Traditional Chinese medicine (TCM) has profound theoretical basis and cultural heritage, and under the guidance of TCM theory, herbal medicines have been used effectively to combat epidemics’ infections and save many lives. TCM and conventional Western medicine are both considered mainstream medicine, with the support and promotion of the government of China. In China, there are thousands TCM hospitals and many well-trained TCM practitioners provide TCM treatments and services to patients. TCM service network has been established with the framework of comprehensive Chinese medicine hospitals, specialized Chinese medicine hospitals, Chinese medicine departments of general hospitals, community health service institutions, and community-oriented Chinese medicine outpatient departments and Chinese medicine clinics. The above measures form a complete traditional medical management system. As an effective means of prevention and treatment of diseases, TCM is consistent with the changes in current health concept and medical mode.
Formulated Chinese medicine has been used in managing previous pandemics, such as SARS-CoV, MERS-CoV, and seasonal epidemics caused by influenza viruses.10 During the epidemic of COVID-19, the use of herbal medicines for prevention and treatment of various ailments is rising around the world because they are safe and effective, while the demand for medicinal plants has increased significantly.11 According to the literature, three TCM drugs and three herbal formulas Chinese medicines were recommended in the treatment of COVID-19 patients, including Jinhua Qinggan granule, Lianhua Qingwen capsule, Xuanfeibaidu granules, Huashibaidu granules, Xuebijing and Detoxifying Decoction, for these formulated showed the most significant efficacy for COVID-19 patients.12
In this article, we reported the possible mechanism and effects of TCM on cardiovascular injury in patients with COVID-19 infection.
Methods
We performed a comprehensive literature search in June 2023 of PubMed, EMBASE, Medline, and “Chinese National Knowledge Infrastructure” focusing on human studies published in English. The main search terms were “coronavirus disease 2019”, “cardiovascular injury”, “SARS-CoV”, “traditional Chinese medicine”, “angiotensin converting enzyme 2”, “inflammation”, “cardiovascular disease”, “chronic heart failure”, “arrhythmia”, and “acute cardiac injury”. The highest quality studies were included in the review, including cohort studies, interventional studies, and meta-analyses. Unpublished and noncommercial publications were excluded.
Possible Mechanism of Cardiovascular Damage in Patients with SARS-CoV-2 Infection and the Effect of TCM
Angiotensin converting enzyme 2 (ACE2) is a functional receptor on cell surfaces, through which virus, including SARS-CoV and SARS-CoV-2, enters the host cells and is highly expressed in the heart.13 SARS-CoV-2 causes an intense systemic inflammatory response, and the release of proinflammatory cytokines leads to a diffuse endotheliitis and procoagulant activity, which contributes significantly to both immune and cardiovascular mechanisms behind myocardial injury.8,14 SARS-CoV-2 disrupts the balance of ACE/ACE2, cardiovascular tissues, or cells that express ACE2, which ultimately leads to COVID-19 progression, especially in patients with CVD and may exacerbate cardiovascular disease in the short and long term.
Prescription mining and molecular dynamics simulations have shown that the main active component of Eriobotrya japonica, 23-trans-p-coumaryhormentic acid, has the best binding affinity for the recognition interface between SARS-CoV-2 S protein and ACE2. Upon binding with 23-trans-pcoumaryhormentic acid, the key interactions between the SARS-CoV-2 S protein and ACE2 are almost completely interrupted, and thus, it can play a role in the prevention or treatment of COVID-19,15 similar effects are also seen after the administration of the TCM Lianhuaqingwen, emodin, and glycyrrhizin acid.16–18 Furthermore, network pharmacology has shown that Yinhua Qinggan granules regulate multiple signaling pathways by binding ACE2 to prevent COVID-19.19 Fifty studies have demonstrated that glycyrrhizin and licorice extract exhibit antiviral activity by disrupting viral uptake into the host cells and destroying the SARS-CoV2 and ACE2 receptor-binding domain.20
Pathological examination of adults who died of COVID-19 shows a large number of inflammatory cells in their organs and tissues and inflammatory infiltration of interstitial monocytes in the myocardium.21 Inflammatory cells infiltration increases myocardial cell apoptosis and the release of pro-inflammatory factors causes heart injury.22 Virus-induced cellular autoimmune response results in myocarditis, which lead to myocardial interstitial edema with myocardial and interstitial connective tissue necrosis. Myocarditis may progress to dilated cardiomyopathy.23,24 Moreover, approximately 20–30% of patients with COVID-19 develop myocarditis.25 Reducing the number and severity pro-inflammatory cell infiltration and reducing associated edema may help prevent the development of COVID-19 induced heart disease and HF (Figure 1).
 |
Figure 1 Etiology and Symptoms of Acute Effects of Viral Infection on the Cardiovascular System. Abbreviation: ACE2, angiotensin converting enzyme 2. |
Based on previous literature, after acute infection, inflammatory activity increases, platelet activation, increased thrombi synthesis, and impaired fibrinolytic function have increased myocardial damage.26 In patients with COVID-19, an imbalance in T-helper 1 (Th1) and Th2 responses contributes to the cytokine storm as the most aggressive response to COVID-19, interleukin (IL)-1, IL-6, and IL-17, TNF-α, elevated levels of inflammatory mediators in tissue samples.27–29 Cytokines can adversely affect cardiac function by promoting myocardial expression of monocytes, neutrophils, and lymphocytes. The accumulation of inflammatory cells in the heart muscle may impair the heart function, which can lead to HF. In addition, the effects of cytokines may also directly affect cardiac function. Cytokine storms may be related to disease severity and observed effects on the cardiovascular system and cause myocardial damage.30,31 Preventing inflammation caused by COVID-19 can help prevent pathological events leading to heart damage.
Administration with “three formulas and three medicines” reduce the level of IL-6 in each clinical stage of COVID-19, which include active ingredients including quercetin, ursolic acid, and rutin.32,33 Furthermore, the production of pro-inflammatory cytokines (TNF-α, IL-6, CCL-2, and CXCL-10/IP-10) is markedly reduced by the administration of Lianhuaqingwen34 and Shufengjiedu.35 Computational modeling has shown that berberine significantly inhibits the expression of ACE2, in patients infected with SARS-CoV-2.36 Keguan-1 and Huashi Baidu prescriptions significantly inhibit the severe progression of COVID-19 by decreasing the production of proinflammatory factors.37,38
Possible Effects of TCM on COVID-19 Patients with Cardiovascular Disease
Recent decades have seen remarkable progress in TCM research, and TCM has been shown to play an important role in the treatment of cardiovascular disease. The use of TCM to restore cardiac function has been increasingly studied as a therapeutic strategy for cardiovascular disease (Table 1). Furthermore, there is a correlation between the regulation by TCM and the prevention and control of prevention and control of cardiovascular disease with COVID-19.
 |
Table 1 Mechanism of TCM Treatment of Cardiovascular Disease |
Chronic Heart Failure
Patients with chronic heart failure (CHF) are prone to develop acute decompensation after infection with SARS-CoV-2, and the progression is often accompanied by high mortality and disability rates.56 Chen et al29 reported that among 99 adult patients with COVID-19, one 61-year-old man with no prior chronic underlying disease died after developing severe HF during treatment. Peng et al57 reported that among 112 adult patients with COVID-19 who had CVD, 40 patients developed HF and 13 patients died, indicating that patients with CVD and COVID-19 had a worse prognosis than those without CVD. TCM has many advantages in treating CHF. TCM can regulate the patient as a whole, enhance the physical and immune functions, improve clinical symptoms and quality of life, and prevent re-hospitalization or death from acute episodes of CHF.58,59
Qili Qiangxin (QQQX) capsule is a traditional Chinese herbal remedy that is listed by the China Food and Drug Administration as a treatment for CHF that reduces heart rate and reverses ventricular remodeling. QQQX capsule is also reported as a potentially effective treatment in the “Chinese Heart Failure Diagnosis and Treatment Guidelines 2018”.60 A randomized trial of 512 patients with CHF who received either placebo or QQQX capsule in addition to their standard medications for the treatment of CHF showed that a reduction in the NT-proBNP concentration of at least 30% was achieved by 47.95% of patients in the QQQX group compared with 31.98% of patients in the placebo group at the 12-week follow-up.58 Another randomized trial reported that 90 patients with CHF with a heart function of grade III and IV who were treated with Lixin pill, Lixin pill plus a small dose of digoxin, or an ordinary dosage of digoxin showed total effective rates in improving heart function of 83.3%, 93.3%, and 90.0%, respectively.61 To observe the effect of Zhuangshenling combined with Western medicine (WM) on cardiac function, 140 patients with CHF were randomly divided into two groups at a 1:1 ratio, all patients received WM therapy, and treatment group additionally received Zhuangshenling. After 12 weeks of treatment, the effective rate of improved cardiac function grading and the BNP concentration were better in the treatment group.62 Many Chinese herbs, including Salvia miltiorrhiza, Panax notoginseng, and Poria cocos, can enhance myocardial contractile force, dilate blood vessels, diuresis, and inhibit ventricular remodeling.39,40,44,63
Arrhythmia
Arrhythmia is a potentially life-threatening complication of COVID-19 infection, arrhythmia in 44% of ICU patients.64 Drug therapy and artificial pacemaker implantation are two main Western methods to treat tachyarrhythmia. However, there is insufficient evidence for the efficacy of certain drug, and the expenditure of artificial pacemakers is too high to fully meet the clinical needs.65 Therefore, it is important to determine timely and effective measures for arrhythmia prevention and economic treatment. There is a high incidence of arrhythmias in COVID-19 patients due to electrolyte and hemodynamic disturbances and high levels of inflammatory stress.66–68 The total prevalence of arrhythmia in patients with COVID-19 in China is 16.7%. Recently, many studies have reported that the advantages of TCM in preventing and treating arrhythmia and can reduce the incidence of complications.
Hua et al69 conducted an RCT trial to evaluate the efficacy and safety of a TCM called Wenxin Keli (WXKL) for the treatment of premature ventricular contractions (PVCs). A total of 1200 eligible participants were randomly assigned to receive WXKL or placebo in a 1:1 ratio. After the four-week treatment period, the frequency of PVCs was significantly reduced in the WXKL group (P < 0.001).
Xin Su Ning (XSN) is the first TCM approved for arrhythmia in accordance with TCM theory in China. A double-blind, placebo-controlled, multicenter clinical trial of XSN involving 861 patients showed that XSN significantly inhibited PVCs.70 Another TCM, Shensong Yangxin (SSYX) capsule, has been proven to improve myocardial infarction and arrhythmia.71 A randomized study of 465 patients with congestive HF showed that SSYX capsule combined with standard treatment suppresses ventricular premature complexes and improves cardiac function.72 SSYX capsule inhibits a variety of myocardial ion channels and improves ventricular remodeling and the electrophysiological channel current, thus improving arrhythmia.
Acute Cardiac Injury and COVID-19
COVID-19 can cause acute myocardial damage and chronic damage to the cardiovascular system, which might be related to severity of the disease and the patient’s prognosis.30 Proposed mechanisms of myocardial injury include direct myocardial cell damage, systemic inflammation, myocardial interstitial fibrosis, interferon-mediated immune response, and hypoxia.73
It has been reported that 62.3% (190/305) of patients with COVID-19 had myocardial injury, and that patients with myocardial injury had more electrocardiographic abnormalities and higher concentrations of inflammatory biomarkers than those without.74 It is essential to identify patients with COVID-19 combined with myocarditis due to the increased mortality in patients with myocardial inflammation and acute respiratory distress syndrome.75 cTnI concentrations are significantly increased in patients with serious COVID-19, research shows that 34.6% of patients with COVID-19 had cardiac injury indicated by an increased cTnl concentration during hospitalization.28 The incidence of acute cardiac injury is reportedly about 13-fold higher in patients with severe COVID-19 requiring ICU admission compared with patients with milder forms of COVID-19, and at least 8.0% of patients with COVID-19 develop acute cardiac injury.76
Tanshinone IIA combined with puerarin can inhibit inflammatory cell concentration and improve hemodynamics by improving cardiac function and reducing myocardial cell destruction.77 Network pharmacology and experimental studies have shown that dried ginger-aconite decoction can ameliorate myocardial apoptosis, myocardial ischemia, and reperfusion injury.78
Coronary Heart Disease
Patients with COVID-19 with hypertension have a poor prognosis.79 The mortality rate is as high as 10.5% in patients with COVID-19 and heart disease in China.80 An increasing number of people in China are taking TCM as an adjuvant treatment for CHD because it is economical and readily available. TCM protects the heart from ischemic injury, improving patient quality of life.79,81,82
Tongxinluo (TXL) was registered with the China State Food and Drug Administration.83 TXL has been shown to significantly increase the ejection fraction, promote angiogenesis in the peri-infarct region, protect against pressure overload-induced HF, and substantially decrease fibrosis and the size of the infarcted area.84,85 TXL significantly promotes cardiac repair through a novel mechanism involving exosomal transfer of miR146a-5p targeting the IRAK1/NF-κB p65 pathway. Pretreatment with a single low loading dose of TXL 1 hour before myocardial ischemia attenuates no-reflow and ischemia-reperfusion injury by regulating endothelial nitric oxide synthase via the PKA pathway.86 In addition, TXL protects human cardiomyocytes from ischemia/reperfusion injury.83
Wang et al87 assessed the clinical efficacy of danlou tablet on angina pectoris of CHD. Sixty-six patients with CHD angina were assigned to the treatment group (treated with danlou tablet + WM, n=33) or the control group (treated with WM, n=33). After 28 days of treatment, the total effective rate in the treatment group (81.2%) was significantly higher than in the control group (43.3%, P < 0.05).
Ge et al88 performed a multicenter, double-blind, randomized clinical trial to determine the effects of Shexiang Baoxin pill (SXBX) as an aid to optimal drug therapy in patients with stable CAD. T From China’s 97 hospitals, 2674 patients with stable CAD according to the proportion of 1:1 randomized to the SXBX or placebo group. Both groups received optimal medical therapy in accordance with local tertiary hospital protocols. After 24 months of treatment, the occurrence of major adverse cardiovascular events was reduced by 26.9% in the SXBX group compared with the placebo group. Furthermore, the frequency of angina was significantly reduced in the SXBX group at 18 months (P = 0.0362). The authors concluded that SXBX is safe and significantly reduces the frequency of angina in patients with stable CAD.
Conclusion
During the novel COVID-19 epidemic, there have been many patients with CVD complicated by COVID-19, viral infection may damage the cardiovascular system via an unclarified pathogenic mechanism. Based on the available investigation, there is a paucity of data on the treatment of SARS-CoV-2 infection in people with cardiac injury by TCM. In this review, based on the available evidence and the latest research, we comprehensively evaluated the impact of TCM in people with SARS-CoV-2 infection and cardiac injury, as well as the possible mechanisms of each process. TCM had a role to play at all stages of viral infection, and the core principles and practices of TCM remain the same, with treatment being adjusted according to different patterns on the basis of the national protocol. Early TCM intervention helped to reduce progression to serious disease, especially for the elderly. For patients with mild or moderate, TCM intervention including TCM medicines combined with specific acupuncture, moxibustion, transdermal therapy, and Tai Chi exercises can shorten the time to resolution of symptoms and viral clearance. For patients with severe disease and in a critical condition, TCM intervention was applied as an accompaniment to conventional medicine, it was noted that the proportion of patients progressing to severe disease appeared to be reduced among those receiving TCM. During the convalescence stage, TCM interventions were reported to improve the quality of life and clinical symptoms, such as anorexia and fatigue. Patients with CVD may be at greater risk of severe complications after infection with SARS-CoV-2. Patients with CVDs, such as congestive HF and hypertension, should pay particular attention to virus prevention and avoid infection while adhering to the treatment of basic diseases. TCM plays an important role in the prevention, treatment, and recovery of CVDs, but it still needs high-level evidence to support.
Funding
This work was supported by Henan Province COVID-19 Traditional Chinese Medicine Scientific Research Special Project (2022ZYFY02), Henan Province Special Project of Traditional Chinese Medicine Scientific research (2019AZB006, 2019JDZX2096, and 2022JDZX154), and Science and Technology Research Project of Henan Province (222102310570).
Disclosure
The authors declare that there are no competing interests in this work.
References
1. World Health Organization. Press conferences on COVID-19 and other global health issues. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
2. Parohan M, Yaghoubi S, Seraji A. Cardiac injury is associated with severe outcome and death in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Eur Heart J Acute Cardiovasc Care. 2020;9(6):665–677. doi:10.1177/2048872620937165
3. Lala A, Johnson KW, Januzzi JL, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020;76(5):533–546. doi:10.1016/j.jacc.2020.06.007
4. Yu Y, Xu D, Fu S, et al. Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study. Crit Care. 2020;24(1):219. doi:10.1186/s13054-020-02939-x
5. Lindholt JS, Søgaard R, Rasmussen LM, et al. Five-year outcomes of the Danish cardiovascular screening (DANCAVAS) trial. N Engl J Med. 2022;387(15):1385–1394. doi:10.1056/NEJMoa2208681
6. Kite TA, Ludman PF, Gale CP, et al. International prospective registry of acute coronary syndromes in patients with COVID-19. J Am Coll Cardiol. 2021;77(20):2466–2476. doi:10.1016/j.jacc.2021.03.309
7. Ng TM, Toews ML. Impaired norepinephrine regulation of monocyte inflammatory cytokine balance in heart failure. World J Cardiol. 2016;8(10):584–589. doi:10.4330/wjc.v8.i10.584
8. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/s0140-6736(20)30566-3
9. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323(16):1612–1614. doi:10.1001/jama.2020.4326
10. Hu C, Liang M, Gong F, He B, Zhao D, Zhang G. Efficacy of lianhua qingwen compared with conventional drugs in the treatment of common pneumonia and COVID-19 pneumonia: a meta-analysis. Evid Based Complement Alternat Med. 2020;2020:5157089. doi:10.1155/2020/5157089
11. Zeng SY, Liu YF, Liu JH, Zeng ZL, Xie H, Liu JH. Potential effects of akkermansia muciniphila in aging and aging-related diseases: current evidence and perspectives. Aging Dis. 2023;2023:1. doi:10.14336/ad.2023.0325
12. Liu Z, Guo F, Wang Y, et al. BATMAN-TCM: a bioinformatics analysis tool for molecular mechanism of traditional Chinese medicine. Sci Rep. 2016;6:21146. doi:10.1038/srep21146
13. Tai W, He L, Zhang X, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17(6):613–620. doi:10.1038/s41423-020-0400-4
14. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci. 2004;25(6):291–294. doi:10.1016/j.tips.2004.04.001
15. Zhang XZ, Gao Y, Liu Y, et al. Screening of potential inhibitors against SARS-CoV-2 based on prescription mining and molecular dynamics simulations. Prog Biochem Biophys. 2022:1–13. doi:10.16476/j.pibb.2022.0224
16. Chen X, Wu Y, Chen C, et al. Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening. Acta Pharm Sin B. 2021;11(1):222–236. doi:10.1016/j.apsb.2020.10.002
17. Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2007;74(2):92–101. doi:10.1016/j.antiviral.2006.04.014
18. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361(9374):2045–2046. doi:10.1016/s0140-6736(03)13615-x
19. Pu-yang G, Yu-jie G, Xiao-peng L, Nan W, Jian G. Exploring active compounds of Jinhua Qinggan Granules for prevention of COVID-19 based on network pharmacology and molecular docking. Chinese Traditional and Herbal Drugs. 2020;51(07):1685–1693.
20. Gomaa AA, Abdel-Wadood YA. The potential of glycyrrhizin and licorice extract in combating COVID-19 and associated conditions. Phytomed Plus. 2021;1(3):100043. doi:10.1016/j.phyplu.2021.100043
21. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:10.1016/s2213-2600(20)30076-x
22. Xu B, Sun X. Inflammation in the myocardial injury and repair. J Clin Cardiol. 2018;34(7):633–635. doi:10.13201/j.issn.1001-1439.2018.07.001
23. Imanaka-Yoshida K. Inflammation in myocardial disease: from myocarditis to dilated cardiomyopathy. Pathol Int. 2020;70(1):1–11. doi:10.1111/pin.12868
24. Xu HF, Meng L, Yao J, et al. Myocardial expression of Spry1 and MAPK proteins of viral myocarditis. Fa Yi Xue Za Zhi. 2013;29(3):164–167.
25. Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–1687. doi:10.1093/cvr/cvaa106
26. Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. N Engl J Med. 2019;380(2):171–176. doi:10.1056/NEJMra1808137
27. Birra D, Benucci M, Landolfi L, et al. COVID 19: a clue from innate immunity. Immunol Res. 2020;68(3):161–168. doi:10.1007/s12026-020-09137-5
28. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/s0140-6736(20)30183-5
29. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/s0140-6736(20)30211-7
30. Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, et al. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther. 2021;19(3):345–357. doi:10.1080/14787210.2020.1822737
31. Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi:10.1016/j.ebiom.2020.102763
32. Niu WH, Wu F, Cao WY, Wu ZG, Chao YC, Liang C. Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6. Biosci Rep. 2021;41(1). doi:10.1042/BSR20202583
33. Ruan X, Du P, Zhao K, et al. Mechanism of Dayuanyin in the treatment of coronavirus disease 2019 based on network pharmacology and molecular docking. Chin Med. 2020;15:62. doi:10.1186/s13020-020-00346-6
34. Runfeng L, Yunlong H, Jicheng H, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020;156:104761. doi:10.1016/j.phrs.2020.104761
35. Xia L, Shi Y, Su J, et al. Shufeng Jiedu, a promising herbal therapy for moderate COVID-19: Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study. Phytomedicine. 2021;85:153390. doi:10.1016/j.phymed.2020.153390
36. Wang ZZ, Li K, Maskey AR, et al. A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: a computational and mechanistic study. FASEB j. 2021;35(4):e21360. doi:10.1096/fj.202001792R
37. Bai Z, Li P, Wen J, et al. Inhibitory effects and mechanisms of the anti-covid-19 traditional Chinese prescription, Keguan-1, on acute lung injury. J Ethnopharmacol. 2022;285:114838. doi:10.1016/j.jep.2021.114838
38. Wei WL, Wu SF, Li HJ, et al. Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS. Chin J Nat Med. 2021;19(6):473–480. doi:10.1016/s1875-5364(21)60046-8
39. Lin JW, Cherng YG, Chen LJ, Niu HS, Chang CK, Niu CS. Ginseng is useful to enhance cardiac contractility in animals. Biomed Res Int. 2014;2014:723084. doi:10.1155/2014/723084
40. Wu ZL, Ren H, Lai WY, et al. Scleroderma of Poria cocos exerts its diuretic effect via suppression of renal aquaporin-2 expression in rats with chronic heart failure. J Ethnopharmacol. 2014;155(1):563–571. doi:10.1016/j.jep.2014.05.054
41. Ma J, Ma S, Yin C, Wu H. Shengmai San-derived herbal prevents the development of a vulnerable substrate for atrial fibrillation in a rat model of ischemic heart failure. Bio Pharmaco. 2018;100:156–167. doi:10.1016/j.biopha.2018.02.013
42. Li C, Wang Y, Qiu Q, et al. Qishenyiqi protects ligation-induced left ventricular remodeling by attenuating inflammation and fibrosis via STAT3 and NF-κB signaling pathway. PLoS One. 2014;9(8):e104255. doi:10.1371/journal.pone.0104255
43. Xiao J, Deng SB, She Q, et al. Traditional Chinese medicine Qili qiangxin inhibits cardiomyocyte apoptosis in rats following myocardial infarction. Exp Ther Med. 2015;10(5):1817–1823. doi:10.3892/etm.2015.2759
44. Meng Y, Du Z, Li Y, et al. Integration of metabolomics with pharmacodynamics to elucidate the anti-myocardial ischemia effects of combination of notoginseng total saponins and safflower total flavonoids. Front Pharmacol. 2018;9:667. doi:10.3389/fphar.2018.00667
45. Wang H, Jiang W, Hu Y, et al. Quercetin improves atrial fibrillation through inhibiting TGF-β/Smads pathway via promoting MiR-135b expression. Phytomedicine. 2021;93:153774. doi:10.1016/j.phymed.2021.153774
46. Zhou X, Liu J, Li J. Effects and mechanism of quercetin on blood pressure intestinal flora and ventricular remodeling in spontaneously hypertensive rats. Nat Prod Resd Dev. 2020;32(9):1449–1455. doi:10.16333/j.1001-6880.2020.9.001
47. Liu G, Yang W, Wang Y, Zhang F. The effect of puerarin on the arrhythmia induced by ischemia/reperfusion injury in rats myocardium. Ann Appl Biol. 2020;39(07):3350–3354. doi:10.13417/j.gab.039.003350
48. Guo S, Xue YJ, Zhu X, Yang B, Zhou CZ. Effects and pharmacological mechanism of Zhigancao Decoction on electrical and structural remodeling of the atrium of rabbits induced by rapid atrial pacing. J Interv Card Electrophysiol. 2023;66(3):597–609. doi:10.1007/s10840-022-01356-0
49. Li X, Tian G, Xu L, et al. Wenxin keli for the treatment of arrhythmia-systems pharmacology and in vivo pharmacological assessment. Front Pharmacol. 2021;12:704622. doi:10.3389/fphar.2021.704622
50. Xu H, Lu R, Liu N, Wen F. Antiarrhythmic effect and mechanism of Anlv capsule. Chin J Gerontol. 2019;39(12):2836–2838.
51. Yang Y, Su C, Zhang XZ, et al. Mechanisms of Xuefu Zhuyu Decoction in the treatment of coronary heart disease based on integrated metabolomics and network pharmacology approach. J Chromatogr B Analyt Technol Biomed Life Sci. 2023;1223:123712. doi:10.1016/j.jchromb.2023.123712
52. Gao J, Pan Y, Zhao Y, et al. Network pharmacology study on molecular mechanisms of Zhishi Xiebai Guizhi decoction in the treatment of coronary heart disease. Evid Based Complement Alternat Med. 2021;2021:3574321. doi:10.1155/2021/3574321
53. Zhang J, Xue S, Chen H, et al. Exploring the mechanism of si-miao-yong-an decoction in the treatment of coronary heart disease based on network pharmacology and experimental verification. Comb Chem High Throughput Screen. 2023;26. doi:10.2174/1386207326666230703150803
54. Cui Y, Zhang F, Xu W, et al. Effects of Si-Miao-Yong-An decoction on myocardial I/R rats by regulating gut microbiota to inhibit LPS-induced TLR4/NF-κB signaling pathway. BMC Complement Med Ther. 2023;23(1):180. doi:10.1186/s12906-023-04013-9
55. Fan Y, Liu J, Miao J, et al. Anti-inflammatory activity of the Tongmai Yangxin pill in the treatment of coronary heart disease is associated with estrogen receptor and NF-κB signaling pathway. J Ethnopharmacol. 2021;276:114106. doi:10.1016/j.jep.2021.114106
56. Rey JR, Caro-Codón J, Rosillo SO, et al. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020;22(12):2205–2215. doi:10.1002/ejhf.1990
57. Yudong P, Kai M, Hongquan G, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Chin J Cardiol. 2020;48:450–455. doi:10.3760/cma.j.cn112148-20200220-00105
58. Li X, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol. 2013;62(12):1065–1072. doi:10.1016/j.jacc.2013.05.035
59. Lu X, Zhang L, Wang J, et al. Clinical efficacy and safety of xinmailong injection for the treatment of chronic heart failure: a meta-analysis. Front Pharmacol. 2018;9:810. doi:10.3389/fphar.2018.00810
60. Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Heart Failure Professional Committee of Chinese Medical Doctor Association, Editorial Board of the Chinese Journal of Cardiovascular Diseases. Chinese heart failure diagnosis and treatment guidelines 2018. Chin J Cardiol. 2018;46(10):760–789. doi:10.3760/cma.j.issn.0253-3758.2018.10.004
61. Li L, Zhang J, Xu F. Clinical study on lixin pill in treating congestive heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000;20(5):341–343.
62. Fu XX, Lu J, Yang F, Xiao WJ. Treatment of chronic heart failure of Xin-Shen yang deficiency, interior retention of water-fluid syndrome by external application of Zhuangshenling recipe combined with western medicine: a clinical study. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014;34(7):808–811.
63. Jiang B, Chen J, Xu L, et al. Salvianolic acid B functioned as a competitive inhibitor of matrix metalloproteinase-9 and efficiently prevented cardiac remodeling. BMC Pharmacol. 2010;10:10. doi:10.1186/1471-2210-10-10
64. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):1504–1507. doi:10.1016/j.ajem.2020.04.048
65. He H, Han G, Li X, et al. Efficacy and safety of Chinese medicine in treating arrhythmia: meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2021;2021:9960471. doi:10.1155/2021/9960471
66. Alexander LK, Keene BW, Small JD, Yount B, Baric RS. Electrocardiographic changes following rabbit coronavirus-induced myocarditis and dilated cardiomyopathy. Adv Exp Med Biol. 1993;342:365–370. doi:10.1007/978-1-4615-2996-5_56
67. Wu CI, Postema PG, Arbelo E, et al. SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. Heart Rhythm. 2020;17(9):1456–1462. doi:10.1016/j.hrthm.2020.03.024
68. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;31(5):1003–1008. doi:10.1111/jce.14479
69. Hua W, Gao RL, Zhao BC, et al. The efficacy and safety of wenxin keli in patients with frequent premature ventricular contractions: a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. Chin Med J. 2015;128(19):2557–2564. doi:10.4103/0366-6999.166026
70. Wang X, Wang T, Ding S, Ma YL. Xin su ning-a review of basic and clinical pharmacology integrated with traditional Chinese medicine antiarrhythmic theory. Front Pharmacol. 2021;12:657484. doi:10.3389/fphar.2021.657484
71. Yang HJ, Kong B, Shuai W, Zhang JJ, Huang H. Shensong yangxin protects against metabolic syndrome-induced ventricular arrhythmias by inhibiting electrical remodeling. Front Pharmacol. 2020;11:993. doi:10.3389/fphar.2020.00993
72. Wang X, Hu D, Dang S, et al. Effects of traditional Chinese medicine shensong yangxin capsules on heart rhythm and function in congestive heart failure patients with frequent ventricular premature complexes: a randomized, double-blind, multicenter clinical trial. Chin Med J. 2017;130(14):1639–1647. doi:10.4103/0366-6999.209906
73. Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: possible mechanisms. Life Sci. 2020;253:117723. doi:10.1016/j.lfs.2020.117723
74. Giustino G, Croft LB, Stefanini GG, et al. Characterization of myocardial injury in patients with COVID-19. J Am Coll Cardiol. 2020;76(18):2043–2055. doi:10.1016/j.jacc.2020.08.069
75. Jaiswal V, Sarfraz Z, Sarfraz A, et al. COVID-19 infection and myocarditis: a state-of-The-Art systematic review. J Prim Care Community Health. 2021;12:21501327211056800. doi:10.1177/21501327211056800
76. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–538. doi:10.1007/s00392-020-01626-9
77. Gao S, Li L, Li L, et al. Effects of the combination of tanshinone IIA and puerarin on cardiac function and inflammatory response in myocardial ischemia mice. J Mol Cell Cardiol. 2019;137:59–70. doi:10.1016/j.yjmcc.2019.09.012
78. Xie F, Wu YY, Duan GJ, et al. Anti-myocardial ischemia reperfusion injury mechanism of dried ginger-aconite decoction based on network pharmacology. Front Pharmacol. 2021;12:609702. doi:10.3389/fphar.2021.609702
79. Wang J, He QY, Zhang YL. Effect of shenshao tablet on the quality of life for coronary heart disease patients with stable angina pectoris. Chin J Integr Med. 2009;15(5):328–332. doi:10.1007/s11655-009-0328-0
80. Shaha KB, Manandhar DN, Cho JR, Adhikari A, KC MB. COVID-19 and the heart: what we have learnt so far. Postgrad Med J. 2021;97(1152):655–666. doi:10.1136/postgradmedj-2020-138284
81. Wu HL, Wang X, Li XM, Luo WJ, Deng TT. Trial study on DENG Tie-tao’s coronary heart disease capsules in improving patients’ quality of life. Chin J Integr Med. 2005;11(3):173–178. doi:10.1007/bf02836499
82. Wei H, Wu H, Yu W, Yan X, Zhang X. Shenfu decoction as adjuvant therapy for improving quality of life and hepatic dysfunction in patients with symptomatic chronic heart failure. J Ethnopharmacol. 2015;169:347–355. doi:10.1016/j.jep.2015.04.016
83. Chen GH, Xu CS, Zhang J, et al. Inhibition of miR-128-3p by tongxinluo protects human cardiomyocytes from ischemia/reperfusion injury via upregulation of p70s6k1/p-p70s6k1. Front Pharmacol. 2017;8:775. doi:10.3389/fphar.2017.00775
84. Li Q, Li N, Cui HH, et al. Tongxinluo exerts protective effects via anti-apoptotic and pro-autophagic mechanisms by activating AMPK pathway in infarcted rat hearts. Exp Physiol. 2017;102(4):422–435. doi:10.1113/ep086192
85. Wang B, Yang Q, Bai WW, et al. Tongxinluo protects against pressure overload-induced heart failure in mice involving VEGF/Akt/eNOS pathway activation. PLoS One. 2014;9(6):e98047. doi:10.1371/journal.pone.0098047
86. Li XD, Yang YJ, Geng YJ, et al. Tongxinluo reduces myocardial no-reflow and ischemia-reperfusion injury by stimulating the phosphorylation of eNOS via the PKA pathway. Am J Physiol Heart Circ Physiol. 2010;299(4):H1255–61. doi:10.1152/ajpheart.00459.2010
87. Wang S-H, Wang J, Li J. 丹蒌片治疗痰瘀互阻型冠心病心绞痛的疗效评价[Efficacy assessment of treating patients with coronary heart disease angina of phlegm and stasis mutual obstruction syndrome by Danlou tablet]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012;32(8):1051–1055. Chinese.
88. Ge JB, Fan WH, Zhou JM, et al. Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled Phase IV randomized clinical trial. Chin Med J. 2020;134(2):185–192. doi:10.1097/cm9.0000000000001257
© 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.